Expression of p53 and bcl-2 in adenomas and colorectal carcinoma;Expresion de p53 y de bcl-2 en adenomas y carcinomas colorrectales

Medicina

Volumn 57, Issue 6, 1997, Pages 662-666

  Sundblad, Alberto S ^a   Chumbita, Rosa L ^a   Zoppi, Jorge A ^a  

^a HOSPITAL PRIVADO DE COMUNIDAD   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADENOMA; ADENOMATOUS POLYP; AGED; ARTICLE; CARCINOMA; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; ADENOMATOUS POLYPS; AGED; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, P53; HUMANS; MALE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031306098     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vogelstein B, Kingler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
2. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutation in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
3. Harris AL. Mutant p53. The commonest genetic abnormality in human cancer? Editorial. J Pathol 1990; 162: 5-6.
4. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
5. Lane DP. p53 and human cancers. Br Med Bull 1994; 50: 528-99.
6. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-5.
7. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-48.
8. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 1994; 69: 846-52.
9. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alterations in human cancer: a review. Int J Cancer. 1994; 57: 1-9.
10. Hockenbery DM: The bcl-2 oncogene and apoptosis. Semin Immunol 1992; 4: 413-20.
11. Korsmayer SJ: Bcl-2: an antidote to programmed cell death. Cancer Surveys 1992; 15: 105-18.
12. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26.
13. Weiss LM, Chang KL. The bcl-2 proto-oncogene. Appl Immunohistochem 1993; 1: 163-5.
14. Diebold J, Baretton G, Felchner M, Meier W, Dopfler K, Schmidt M, et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian cancer. Am J Clin Pathol 1996; 105: 341-9.
15. Doglioni C, Dei-Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994; 424: 47-51.
16. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 1995; 75: 2209-13.
17. Pezzella F, Turley H, Kuzu Y et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-4.
18. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierott MA, Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 1994; 18: 1054-64.
19. Leek RD, Kaklamanis L, Pezzella F et al. Harris AL, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-9.
20. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfler K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 1996; 77: 255-64.
21. Nakamura S, Akazawa K, Kinukawa N, Yao T, Tsuneyoshi M. Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma. Hum Pathol 1996; 27: 225-33.
22. Rosai J. Ackerman's Surgical Pathology, Vol I, S. Louis, Mosby, 1996; p. 765.
23. Konishi F, Morson B. Pathology of colorectal adenomas. A colonoscopic survey. J Clin Pathol 1982; 35: 830-41.
24. Pellicer EM, Sundblad A. Recuperación de antígenos por homo de microondas. Medicina (Buenos Aires) 1994; 54: 129-32.
25. Batsakis JG, El-Naggar AK. p53: fifteen years after discovery. Adv Anat Pathol 1995; 2:71-88.
26. Kaklamanis L, Savage A, Mortensen N, Tsiotos P. Doussis-Augnostopoulou I, Biddolphs S, et al. Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 1996; 179: 10-4.
27. Bass IO, Mulder J, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in arcival colorectal neoplasms. J Pathol 1994; 172: 5-12.
28. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrial subtypes. Gynecol Oncol 1996; 61: 167-74.
29. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994; 73: 2900-4.
30. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.